WO2001010413A2 - Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers - Google Patents
Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers Download PDFInfo
- Publication number
- WO2001010413A2 WO2001010413A2 PCT/EP2000/007546 EP0007546W WO0110413A2 WO 2001010413 A2 WO2001010413 A2 WO 2001010413A2 EP 0007546 W EP0007546 W EP 0007546W WO 0110413 A2 WO0110413 A2 WO 0110413A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- lipid
- periodic structures
- disorder
- pharmaceutically usable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
Definitions
- Periodic structures comprising lipids, polyelectrolytes, and structure-inducing soluble oligovalent linkers, and biological use thereof
- the invention relates to a method for preparing pharmaceutically usable compositions which comprise periodic structures consisting of polyelectrolytes sandwiched between lipid aggregates having at least one charged component, and the use thereof; it further relates to a kit comprising, in a bottled or otherwise packaged form, at least one dose of said pharmaceutically usable composition.
- Assemblies of lipid membranes and DNA have attracted large interest as artificial carriers of genetic material, being suitable for the use in gene therapy and DNA vaccination.
- various complexes of DNA and cationic lipids (CL) were tested without that the details of CL-DNA were completely understood or perfectly controlled to date.
- CL-DNA complexes over natural, viral gene vectors include the absence of a viral DNA and a greatly reduced immunogenicity.
- the main disadvantages are the poor reproducibility of CL-DNA complex formation and relatively low transfection efficiency in comparison with the viral vectors. In order to overcome said deficiencies, it is essential to master better the factors governing complex formation and also to maximise the payload of carriers.
- multilamellar DNA-CL complexes When DNA is interspersed with a suspension of multilamellar lipid vesicles, multilamellar DNA-CL complexes also arise spontaneously. They comprise stacks of lipid bilayers alternating with monolayers of densely packed parallel DNA helices; often, more than 10 lamellae are counted in one complex. CL-DNA complexes for practical applications are usually prepared by mixing DNA solution with an aqueous suspension of liposomes containing CLs. As a result, globular lipid-DNA particles often form, sometimes with a structure similar to that described in preceding paragraph.
- DNA monolayer adsorbs to the template CL bilayer; then, a vesicle from the bulk adsorbs to the bulk side of the DNA monolayer, ruptures, and rolls its bilayer over the complex; the bulk side of this bilayer is now available for further DNA adsorption, and so on.
- DNA can intercalate between the multilayers under the influence of mixing or osmotic stress, e.g. at the sites of maximum membrane curvature, which can easily lead to local bilayer rupture and DNA translocation.
- AF-lps asialofetuin-liposomes
- hepatocytes Hara, T., Aramaki, Y., Takada, S., Koike, K0, Tsuchiya, S., 1995, "Receptor-mediated transfer of pSV2CAT DNA to a human hepatoblastoma cell line HepG2 using asialofetuin-labelled cationic liposomes" in Gene 159: 167-174).
- Plasmid pSV2CAT DNA was associated with such liposomes (AF-lps-pSV2CAT).
- AF-lps was found to bind to HepG2 cells through specific interaction with asialoglycoprotein receptors (AGPR); internalisation follows by the receptor-mediated endocytotic pathway.
- APR asialoglycoprotein receptors
- Transfection of HepG2 cells with AF-lps-pSV2CAT was much stronger than the effects of either pSV2CAT associated with non-derivatised control lps (N-lps- pSV2CAT) or else a mixture of pSV2CAT and empty AF-lps.
- Pretreatment with EDTA- encapsulated AF-lps increased the transfection efficiency of AF-lps- pSV2CAT.
- BMEC bovine brain microvessel endothelial cells
- EDTA a common constituent of many buffers with the charges of similar sign as DNA (a co-ion), drastically and reproducibly affects the morphology of CL-DNA complexes.
- EDTA can promote efficiently the unilamellar-to-multilamellar structures transition.
- oligovalent co-ions including but not limited to EDTA, can beneficially affect the morphology of CL-DNA complexes for practical applications and should influence the efficacy of transfection in vitro and in vivo.
- WO92/0666 discloses multilayer liposomes for thermal water encapsulation.
- the systems described therein generally form multilayer (periodical) structures spontaneously.
- This prior art comprises no teaching, how perdiodical structures can be built from monolayer (non-periodical) vesicles.
- Systems as disclosed in WO92/06666 are e.g. discussed in
- An adsorbent or less generally a carrier, means an aggregate, independent of its composition and/or the nature and /or the source of its generation, capable of associating with one or more charged macromolecules (adsorbates) suitable for a practical purpose, such as application on or the delivery into mammalian body.
- the substrate for the positively charged adsorbates is typically negatively charged, while for the positively charged adsorbates negative adsorbents are preferable.
- An associate by the definition used in this application, is any complex between an adsorbate and a carrier (adsorbent).
- Such an associate typically comprises two or more different kind of molecules, at least one of which forms aggregates with one or several well defined surface(s), independent of the reason for the complex formation but excluding covalent binding.
- Adsorption of polyelectrolyte molecules onto an aggregate surface driven by electrostatic interactions between the differently charged system components is the most frequent type of association, and is also the main topic of this application. Binding of anionic DNA onto an aggregate surface containing cationic molecular 'anchors' is most prominent and practically relevant example for this.
- An oligovalent linker is any molecule with two or more groups capable of binding, non-covalently, to other groups on different molecules. Very often, the binding is of electrostatic nature, such as between chelators and oppositely charged groups on various molecules / ions, but other types of binding, e.g. via hydrogen bonds or directed dispersion forces, are also possible.
- a chelator within the framework of this disclosure, denotes any molecule capable of bringing and/or keeping together two charged entities whether dissolved or (partially) aggregated, independent of whether or not the underlying force is of electrostatic or some other origin. (Further possible interactions include H-bonds or other non-covalent forces.)
- An extended stable lipid aggregate typically contains more than a few hundred molecules. Most often, and advantageously, it takes the form of a macroscopic monolayer or a bilayer, depending on the purpose of a formulation.
- a lipid in the sense of this invention, is any substance with characteristics similar to those of fats or fatty materials.
- molecules of this type possess an extended apolar region (chain, X); often they also have a water-soluble, polar, hydrophilic group, so-called head-group (Y).
- Basic structural formula 1 for lipids therefore reads
- n being greater than or equal to zero and m typically exceeding the value of 3 (and more often of 6 and in most cases of 10).
- lipids are well known in the art. Many lipids and phospholipids which form stable aggregates, most often in the form of bilayer vesicles are described in above mentioned patents and patent applications and are surveyed in 'Phospholipids Handbook' (Cevc, G., ed., Marcel Dekker, New York, 1993); 'An Introduction to the Chemistry and Biochemistry of Fatty acids and Their Glycerides' (Gunstone, F.D., ed.) and 'Lipids' (D. M. Small, ed., Plenum Press, London). A survey of commercial surfactants, some of which may be suitable for the purposes of this application, is given in Handbook of Industrial Surfactants, M. Ash & I. Ash, eds., Gower).
- a cationic amphiphile with the basic formula similar to (1) except in that Y - Y + , which can act as an anchor for polyelectrolytes in the associate, is a substance that remains an integral part of the adsorbent during polyelectrolyte-substrate (carrier) association process.
- Monoamines that advantageously can take the role of Y “1" , include ethanolamine, methylamine, dimethylamine and trimethylamine, ethylamine, diethylamine and triethylamine, n-propylamine, n-butylamine, etc., furthermore methoxyamine, 2-methoxyethylamine, and 2-ethoxyethylamine; diamines, such as ethylenediamine, 1,3-diaminopropane, 1,3-diaminobutane, etc., hydrazine, putrescine, and cadaverine; polyamines, spermine and spermidine; amides, such as acetamide, propionamide, and isonicotinic acid hydrazide, or semicarbazide, etc..
- An anionic anchor differs from the corresponding cationic anchor functionally in the sign of its charges (Y -» Y " ).
- any group with a pK below the pH value of formulation containing periodic structures can take the role of Y " .
- a representative list of such groups can be found in CRC Handbook of Chemistry and Physics, for example; a comprehensive list of corresponding anchors is given in Handbook of Cationic Surfactants should be considered; both documents are incorporated herein by reference.
- a polyelectrolyte (a charged macromolecule) is any straight or branched chain molecule with charges, which are more often than not concentrated in/along molecular segments, along the chain. This includes poly-cations as well as poly- anions, mixed forms being also possible.
- the group of poly-anions encompasses, amongst others, oligo or polynucleotides, such as homo- or hetero-chains of desoxyribonucleic- (DNA) or ribonucleic acid
- RNA especially the genomic DNA, cDNA and mRNA that encode for therapeuticall their chemical, biological, or molecular biological (genetic) modifications or derivatives, etc., with at least 4 charges per chain.
- the group of nucleotides includes adenine, adenosine, adenosine-3',5'-cyclic monophosphate, n6,o2'dibutyryl, adenosine-3',5'-cyclic monophosphate, n6,o2'-dioctanoyl, adenosine, n6-cyclohexyl, salts of adenosine-5'-diphosphate, adenosine-5'- monophosphoric acid, adenosine-5'-o-(3-thiotriphosphate), salts of adenosine-5'- triphosphate, 9-beta-D-arabinoturanosyladenine, 1 -beta-D- arabinoturanosy
- poly(DA) ss poly(A) ss, poly(C) ss, poly(G) ss, poly(U) ss, poly(DA)-(DT) ds, complementary homopolymers, poly (D(A-T)) ds, copolymers, poly(DG)»(DC) ds, complementary homopolymers, poly (d(GC)) ds copolymers, poly (d(L-C)) ds copolymers, poly(I)-poly(C) ds, etc..
- genomic DNA, cDNA and mRNA that encodes for therapeutically useful proteins as are known in the art, ribosomal RNA; further antisense polynucleotides. whether RNA or DNA, that are useful to inactivate transcription products of genes, and which are useful e.g. as therapies to regulate the growth of cells in diseased mammals; or ribozymes.
- the group of poly-cations includes certain poly-amino acids, such as poly-lysine.
- the group of poly-cations includes certain poly-amino acids, such as poly-lysine.
- biocide describes any ingredient added with the purpose of improving biological stability of the formulation.
- An exemplary list is given in International
- oligovalent linkers are separately made and then mixed to form said periodic structures, the simultaneous presence of said components catalysing the formation of said periodic structures comprising at least one layer of lipid component associated with a layer of polyelectrolyte molecules.
- Said lipid aggregates preferably have the original form of multilamellar, more preferably of unilamellar lipid vesicles or of freely suspended or supported lipid monolayers.
- the polyelectrolytes are selected from the classes of poly- deoxyribonucleic acids, poly-ribonucleic acids, or derivatives thereof.
- said oligovalent linkers belong to the class of chelators.
- Another preference is to use polar lipids for forming lipid aggregates.
- a suspension of lipid aggregates and a polyelectrolyte solution are mixed, to form a relatively stable suspension in a solution, and oligovalent linkers, preferably in a solution, are then added to start or to control otherwise the formation of said periodic structures. It then is advantageous that said periodic structures are suspended or remain suspended in the supporting solution after their formation.
- the average size of plain lipid aggregates is between 30 nm and 5000 nm, preferably is between 20 nm and 1000 nm, more preferably is between 30 nm and 500 nm and most preferably is between 450 nm and 100 nm.
- the concentration of at least one of the above-listed system components and / or the respective relative concentrations are used to control the speed of formation and / or the final size and / or the degree of periodicity for the structures generated in the system. Accordingly, it may be advantageous to select the final size, which for spherical structures corresponds to diameter, of suspended periodic structures is between 10 nm and 10 ⁇ m, preferably is between 20 nm and 2.5 ⁇ m, even more advantageously is between 30 nm and 600 nm or even better between is 40 nm and 350 nm, and most preferably is between 50 nm and 200 nm.
- the chelator is selected amongst EDTA, EGTA, EDDA, EDDS (ethylenediamine-N,N'-disuccinic acid), iminodiacetic acid, or their salts, DMPS (2,3-dimercaptopropane-l-sulfonic-acid), 8-hydroxyquinoline, lipoic acid (thioctic acid), deferoxamine mesilate, polycarboxylate, 2-furildioxime, N-2-hydroxypropyl sulphonic acid aspartic acid,
- N-carboxymethyl N-2 hydroxypropyl 3 sulphonic acid ⁇ -alanine N,N diacetic acid aspartic acid, N,N diacetic acid aspartic acid N-monoacetic acid, iminodisuccinic acid, is an amino acid based chelating agent, such as isoserine diacetic acid (ISDA), 2-phosphonobutane-l,2-4-tricarboxylic acid, GADS, alkyl iminodiacetic acid; dipicolinic acid; hydroxy-l,l-ethylidene diphosphonic acid
- ISDA isoserine diacetic acid
- GADS alkyl iminodiacetic acid
- dipicolinic acid hydroxy-l,l-ethylidene diphosphonic acid
- HEDP HEDP
- a derivative thereof or is some other oligo- or poly-anions and cations, or any other molecules with several polar, polarisable, or otherwise associable groups, which often have hydrogen bond donors and/or acceptors on them.
- lipids from biological sources or made synthetically, directly or by modifying the former lipids, advantageously comprising a glyceride, glycerophospholipid, isoprenoidlipid, sphingolipid, steroid, sterine or sterol, a sulphur- or carbohydrate-containing lipid, or else, any other lipid which forms bilayers, in particular a half-protonated fluid fatty acid, and very frequently a phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol, a phosphatidic acid, a phosphatidylserine, a sphingomyelin or sphingophospholipid, glycosphingolipid (e.g.
- a ganglioside or any other glycolipid or a synthetic lipid in particular with oleoyl-, linoleyl-, linolenyl-, linolenoyl-, arachidoyl-, lauroyl-, myristoyl-, palmitoyl-, stearoyl chains, which can also be attached to the corresponding sphingosine base, is a glycolipid or any other diacyl-, dialkenoyl, dialkyl-lipid or branched aliphatic chain-lipid with two identical or mixed chains.
- Cationic anchors which can be used particularly advantageously belong to the class of lipids with one or several aliphatic chains or other siutable apolar residues, if appropriate branched or derivatised, and a headgroup with one or several positive charges; the latter most often reside on a quaternary or ternary amine, which in case of monoamines includes ethanolamine, methylamine, dimethylamine and trimethylamine, ethylamine, diethylamine and triethylamine, n-propylamine, n-butylamine, etc., furthermore methoxyamine, 2- methoxyethylamine, and 2-ethoxyethylamine; diamines, such as ethylenediamine, 1,3-diaminopropane, 1,3-diaminobutane, etc., hydrazine, putrescine, and cadaverine; polyamines, spermine and spermidine; when an amide can be e.g.
- Preferable choices include N-[l-(2,3-diacyl , N-[l-(2,3-dialkyl)- or N-[l-(2,3-dialkenoyl)propyl]- N,N,N-trialkylammonium, -N,N-dialkylammonium or -N-alkylammonium salt, such as N-[l-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium bromide
- DOTMA 1,2-diacyloxypropyl-N,N-dialkyl-hydroxyalkyl ammonium salt, 1 ,2- dialkenoyloxypropyl-N,N,N-dialkyl-hydroxyalkyl ammonium salt, or -N,N-alkyl- hydroxyalkyl, or N,N,N-alkyl-dihydroxyalkyl, such as 1 ,2-dimyristyloxypropyl- N,N-dimethyl-hydroxyethyl ammonium bromide (DMRIE), [N-(N ⁇ N'- dialkylaminoethane) carbamyol] cholesterol, such as [N-(N', N'- dimethylaminoethane) carbamyol] cholesterol (DC-Choi), or [N-(N'- alkylaminoethane) carbamyol] cholesterol, dialkylamidoglycyl spermine or spermidine, such as dioctade
- DAP l,2-diacyl-3-methylammonium propane
- MAP l,2-diacyl-3-methylammonium propane
- Anionic anchors which are selected most often, or with an advantage, carries a carboxylate, succinate, sulfosuccinate, sulphate, sulphonate, ether sulphate, phosphate, phosphonate or amine oxide, or other anionic substances which also appear in anionic linkers, with some preference for long-chain fatty acid derivatives, alkylsulphate-, phosphate or phosphonate salts, cholate-, deoxycholate-, glycodeoxycholate-, taurodeoxycholate-salts, dodecyl- dimethyl- aminoxides, especially lauroyl- or oleoylsulphate-salts, sodium deoxycholate, sodium glycodeoxycholate, sodium oleate, sodium elaidate, sodium linoleate, sodium laurate or sodium myristate.
- the concentration of charged anchors used in the mixing process is in the range 1-80 mol-%, more preferably is 10-60 mol-%, and most preferably is 20-50 mol-%, the specific chosen value also depending on the selected polyelectrolyte concentration; higher concentrations of latter ingredient typically require a relatively high concentration of charged anchor molecules.
- the total lipid concentration, including charged anchors and basic lipids in the aggregates is 0.0005-30 w-%, more preferably is 0.001-20 w-%, even more preferably is 0.01-15 w-%, and most preferably is 0.05- 10 w-%. It may be advantageous as well that the bulk polyelectrolyte concentration is selected to be in the range 0.0005-30 w-%, more preferably is 0.001-20 w-%, even more preferably is 0.01-15 w-%, and most preferably is 0.05-10 w-%.
- the specific total lipid concentration and polyelectrolyte concentration values are chosen so as to ensure that the resulting periodic structures carry less than 50 % of the original charge density and more preferably less than 25 % of residual charge.
- the formation of (mixed) lipid suspension is induced by substance addition into the fluid phase, evaporation from a reverse phase, by using an injection- or a dialysis procedure, with the aid of mechanical stress, such as shaking, stirring, vibrating, homogenisation, ultrasonication, shear, freezing and thawing, or filtration using convenient driving pressure.
- mechanical stress such as shaking, stirring, vibrating, homogenisation, ultrasonication, shear, freezing and thawing, or filtration using convenient driving pressure.
- the lipid(s) and charged anchor molecules are separately mixed, if required in an organic solution (which in case is eliminated in due time), and the resulting suspension is combined with the solution of polyelectrolytes and the chosen linkers solution under the action of mechanical energy.
- the formation of aggregates with the desired size is ensured by filtration, the filtering material having pores sizes between 0.02 ⁇ m and 0.8 ⁇ m, very frequently between 0.05 ⁇ m and 0.4 ⁇ m, and most frequently between 0.08 ⁇ m and 0.2 ⁇ m, several filters being potentially used in a row or sequentially.
- composition of periodic structures is prepared just before the application, if convenient, from a suitable concentrate or a lyophilisate.
- the composition comprising periodic structures, prepared according to the above-described method, is used to manipulate cells, their metabolism, reproduction or survival. It then may be of an advantage if the composition is used in or on the mammalian body, preferably as drug, drug depot, or some other kind of device with a desirable medical or biological action. It may then be advantageous if said structures contain oligo- or poly-nucleic acids that are either sense or antisense or else comprise an expressible form of a transgene, and are used to deliver said nucleic acids into cells.
- said composition is used for gene delivery, gene therapy or any other kind of modulation of genetic action or in bioengineering; it may furthermore be advantageous for said transgene to encode a protein, which preferably is selected from the group consisting of a ligand, a receptor, an agonist of a ligand, an agonist of a receptor, an antigonist of a ligand, and an antigonist of a receptor. It then also is preferred that said protein is a soluble protein.
- transgene which expresses antisense RNA.
- compositions refers to selection of above-mentioned cells in a mammal with a disorder or a potential disorder, said use then being for treating the disorder or for preventing the potential disorder, as in the case of vaccination.
- Said disorder preferably is an inflammatory disease, dermatosis, kidney or liver failure, adrenal insufficiency, aspiration syndrome, Behcet syndrome, blood disorder, such as cold-haemagglutinin disease, haemolytic anemia, hypereosinophilia, hypoplastic anemia, macroglobulinaemia, trombocytopenic purpura, a bone disorder, cerebral oedema, Cogan's syndrome, congenital adrenal hyperplasia, connective tissue disorder, such as lichen, lupus erythematosus, polymyalgia rheumatica, polymyositis and dermatomyositis, epilepsy, an eye disorder, such as cataracts, Graves' ophthalmopathy, haemangio
- asthenia gravis myasthenia gravis
- pain syndromes such as postherpetic neuralgia, polyneuropathy, pancreatitis
- respiratory disorder such as asthma, rheumatoid disease or osteoarthritis, rhinitis, sarcoidosis
- skin disease such as alopecia, eczema, erythema multiforme, lichen, pemphigus and pemphigoid, psoriasis, pyoderma gangrenosum, urticaria, a thyroid or vascular disorder.
- kits comprising, in a bottled or otherwise packaged form, at least one dose of the pharmaceutically usable composition prepared according to the above-described method designed to be used in or on a mammal for prophylactic purposes, e.g. in the course of vaccination, or for therapy.
- EDTA EDTA
- a solution of linear DNA fragments with an average length of 6 000 bp was prepared by digesting calf thymus DNA (Sigma Chemical Co., USA) with the restriction endonuclease EcoRV (Stratagene, USA).
- the fragments were purified by repeated phenol/chloroform extraction according to standard procedures and exhaustive dialysis against 25 mM triethanolamine buffer (pH adjusted to 7.4 with HC1) through a membrane with a molecular weight cut-off of 3 kDa.
- the lipid mixture used in this study consisted of the cationic lipid 3 ⁇ [N-(N',N ' - dimethylaminoethane)-carbamoyl] cholesterol (DC-Choi, Bachem Biochemica, Heidelberg, Germany) and the zwitterionic lipid l,2-dimyristoyl-sn-glycero-3- phosphocholine (DMPC, Avanti Polar Lipids, Alabaster, AL, USA) at a molar ratio of 2:3. Part of the mixture was dissolved in chloroform to a total lipid concentration of 1 g/L.
- the other part of the mixture was used to prepare small unilamellar vesicles by repeated sequential extrusion through 400 nm to 50 nm polycarbonate filters in the buffer described above. Quasi-elastic light scattering revealed final vesicle diameters of 63 ( ⁇ 22) nm.
- EDTA was added to induce multilayer formation.
- the final DNA concentration in the solution was 6 mg/L, total vesicles concentration was 100 mg/L.
- a Langmuir film at the air water interface was prepared by spreading said mixture from a chloroform solution onto the surface of the suspension of vesicles and DNA solution. To suppress capillary waves, a film of only 300 ⁇ m thickness was used. The temperature was kept constant at 25 ( ⁇ 0.1) °C .
- the wave vector transfer q is a function of X-ray energy and incident angle ⁇ .
- the energy spectrum of the specularly reflected beam was multiplied with a previously recorded calibration function, to correct for the energy distribution of the source, detector sensitivity and secondary effects, such as scattering at the water vapour in the sample chamber. From the calibrated energy spectrum the reflectivity R(q) was obtained.
- the method is given in Vierl, U., Cevc, G., Metzger, H. 1995 "Energy-Dispersive X- ray Reflectivity Study of the Model Membranes at the Air/Water Interface" in Biochim. Biophys. Acta. 1234: 139-143.
- the upper panel of Figure 1 gives the electron density profile of a lipid monolayer at the air- water interface in contact with the suspension of corresponding vesicles and DNA without chelators (linkers) added (example 1). Only a mixed (cationic) lipid monolayer is observed at all times.
- the electron density profile illustrated in lower panel of Figure 1 pertains to the air- water interface covered with a mixed (cationic) lipid monolayer in contact with a suspension of corresponding vesicles and a solution of DNA with EDTA added, after 100 hours of incubation.
- the underlying molecular structure is shown for better reflectogram understanding.
- the multilayers apparent in the lower panel consist of lipid bilayers alternating with monolayers of DNA.
- Low electron densities correspond to the hydrocarbon tail region of lipid bilayers.
- High electron densities correspond to the lipid headgroup regions and intercalated DNA layers.
- the vertical grid corresponds to the repeat distance of surface adsorbed CL-DNA multilayers.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002377422A CA2377422A1 (en) | 1999-08-04 | 2000-08-03 | Periodic structures comprising lipids, polyelectrolytes, and structure- inducing soluble oligovalent linkers, and biological use thereof |
AU72718/00A AU7271800A (en) | 1999-08-04 | 2000-08-03 | Periodic structures comprising lipids, polyelectrolytes, and structure-inducing soluble oligovalent linkers, and biological use thereof |
JP2001514933A JP2003506398A (en) | 1999-08-04 | 2000-08-03 | Periodic structures containing lipids, polyelectrolytes, and structure-inducing soluble low-valent linkers, and methods for their biological use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19936665.9 | 1999-08-04 | ||
DE19936665 | 1999-08-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001010413A2 true WO2001010413A2 (en) | 2001-02-15 |
WO2001010413A3 WO2001010413A3 (en) | 2001-08-16 |
Family
ID=7917131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/007546 WO2001010413A2 (en) | 1999-08-04 | 2000-08-03 | Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP2003506398A (en) |
AU (1) | AU7271800A (en) |
CA (1) | CA2377422A1 (en) |
PL (1) | PL365423A1 (en) |
WO (1) | WO2001010413A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002014548A1 (en) * | 2000-08-10 | 2002-02-21 | Applied Gene Technologies, Inc. | Compositions and methods for nucleic acids sample processing and amplification |
US6448047B2 (en) | 1999-07-30 | 2002-09-10 | Applied Gene Technologies, Inc. | Sample processing to release nucleic acids for direct detection |
WO2003004004A1 (en) * | 2001-07-05 | 2003-01-16 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Pharmacological preparation made from a nanoparticulate mesomorphous polyelectrolyte lipid complex and at least one active ingredient |
US7763663B2 (en) | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
WO2011066651A1 (en) | 2009-12-01 | 2011-06-09 | Protiva Biotherapeutics, Inc. | Snalp formulations containing antioxidants |
KR20160013511A (en) * | 2014-07-25 | 2016-02-04 | 연세대학교 산학협력단 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GRAVES ORBITOPATHY COMPRISING α-LIPOIC ACID |
US9486409B2 (en) | 2006-12-01 | 2016-11-08 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
US9724299B2 (en) | 2006-12-01 | 2017-08-08 | Anterios, Inc. | Amphiphilic entity nanoparticles |
US10016451B2 (en) | 2007-05-31 | 2018-07-10 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
US10016364B2 (en) | 2005-07-18 | 2018-07-10 | University Of Massachusetts Lowell | Compositions and methods for making and using nanoemulsions |
US10532019B2 (en) | 2005-12-01 | 2020-01-14 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US11311496B2 (en) | 2016-11-21 | 2022-04-26 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
CN114650982A (en) * | 2019-11-08 | 2022-06-21 | 中国医学科学院基础医学研究所 | Application of lipid in preparation of nucleic acid delivery agent and related product thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698721A (en) * | 1992-12-17 | 1997-12-16 | Megabios Corporation | Catonic amphiphiles |
US5753262A (en) * | 1995-06-07 | 1998-05-19 | Aronex Pharmaceuticals, Inc. | Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof |
-
2000
- 2000-08-03 AU AU72718/00A patent/AU7271800A/en not_active Abandoned
- 2000-08-03 CA CA002377422A patent/CA2377422A1/en not_active Abandoned
- 2000-08-03 WO PCT/EP2000/007546 patent/WO2001010413A2/en active Application Filing
- 2000-08-03 JP JP2001514933A patent/JP2003506398A/en active Pending
- 2000-08-03 PL PL00365423A patent/PL365423A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698721A (en) * | 1992-12-17 | 1997-12-16 | Megabios Corporation | Catonic amphiphiles |
US5753262A (en) * | 1995-06-07 | 1998-05-19 | Aronex Pharmaceuticals, Inc. | Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof |
Non-Patent Citations (3)
Title |
---|
HUEBNER STEFAN ET AL: "EDTA-induced self-assembly of cationic lipid-DNA multilayers near a monolayer-covered air-water interface." BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1421, no. 1, 21 September 1999 (1999-09-21), pages 1-4, XP000978904 ISSN: 0006-3002 * |
HUEBNER STEFAN ET AL: "Lipid-DNA complex formation: Reorganization and rupture of lipid vesicles in the presence of DNA as observed by cryoelectron microscopy." BIOPHYSICAL JOURNAL, vol. 76, no. 6, June 1999 (1999-06), pages 3158-3166, XP002157729 ISSN: 0006-3495 * |
LASIC D D: "Recent developments in medical applications of liposomes: sterically stabilized liposomes in cancer therapy and gene delivery in vivo" JOURNAL OF CONTROLLED RELEASE,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 48, no. 2-3, 13 October 1997 (1997-10-13), pages 203-222, XP004125857 ISSN: 0168-3659 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6448047B2 (en) | 1999-07-30 | 2002-09-10 | Applied Gene Technologies, Inc. | Sample processing to release nucleic acids for direct detection |
WO2002014548A1 (en) * | 2000-08-10 | 2002-02-21 | Applied Gene Technologies, Inc. | Compositions and methods for nucleic acids sample processing and amplification |
WO2003004004A1 (en) * | 2001-07-05 | 2003-01-16 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Pharmacological preparation made from a nanoparticulate mesomorphous polyelectrolyte lipid complex and at least one active ingredient |
DE10132669A1 (en) * | 2001-07-05 | 2003-01-30 | Fraunhofer Ges Forschung | Pharmacological preparation from a nanoparticulate mesomorphic polyelectrolyte-lipid complex and at least one active ingredient |
DE10132669B4 (en) * | 2001-07-05 | 2008-08-07 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Pharmacological preparation of a nanoparticulate mesomorphic polyelectrolyte-lipid complex and at least one active ingredient |
US7763663B2 (en) | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
US10016364B2 (en) | 2005-07-18 | 2018-07-10 | University Of Massachusetts Lowell | Compositions and methods for making and using nanoemulsions |
US10576034B2 (en) | 2005-12-01 | 2020-03-03 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US10532019B2 (en) | 2005-12-01 | 2020-01-14 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US9486409B2 (en) | 2006-12-01 | 2016-11-08 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
US9724299B2 (en) | 2006-12-01 | 2017-08-08 | Anterios, Inc. | Amphiphilic entity nanoparticles |
US10285941B2 (en) | 2006-12-01 | 2019-05-14 | Anterios, Inc. | Amphiphilic entity nanoparticles |
US10758485B2 (en) | 2006-12-01 | 2020-09-01 | Anterios, Inc. | Amphiphilic entity nanoparticles |
US10905637B2 (en) | 2006-12-01 | 2021-02-02 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
US10016451B2 (en) | 2007-05-31 | 2018-07-10 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
EP2506879A4 (en) * | 2009-12-01 | 2014-03-19 | Protiva Biotherapeutics Inc | Snalp formulations containing antioxidants |
EP2506879A1 (en) * | 2009-12-01 | 2012-10-10 | Protiva Biotherapeutics Inc. | Snalp formulations containing antioxidants |
WO2011066651A1 (en) | 2009-12-01 | 2011-06-09 | Protiva Biotherapeutics, Inc. | Snalp formulations containing antioxidants |
KR20160013511A (en) * | 2014-07-25 | 2016-02-04 | 연세대학교 산학협력단 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GRAVES ORBITOPATHY COMPRISING α-LIPOIC ACID |
KR101680834B1 (en) | 2014-07-25 | 2016-12-01 | 연세대학교 산학협력단 | A pharmaceutical composition for preventing or treating Graves orbitopathy comprising -lipoic acid |
US11311496B2 (en) | 2016-11-21 | 2022-04-26 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
CN114650982A (en) * | 2019-11-08 | 2022-06-21 | 中国医学科学院基础医学研究所 | Application of lipid in preparation of nucleic acid delivery agent and related product thereof |
Also Published As
Publication number | Publication date |
---|---|
PL365423A1 (en) | 2005-01-10 |
AU7271800A (en) | 2001-03-05 |
CA2377422A1 (en) | 2001-02-15 |
WO2001010413A3 (en) | 2001-08-16 |
JP2003506398A (en) | 2003-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chesnoy et al. | Structure and function of lipid-DNA complexes for gene delivery | |
WO2001010413A2 (en) | Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers | |
JP5480764B2 (en) | Amphoteric liposomes and uses thereof | |
CA2335393C (en) | Liposomal encapsulated nucleic acid-complexes | |
JP4175667B2 (en) | Cation reagents for transfection | |
Smith et al. | Toward development of a non-viral gene therapeutic | |
EP2773326B1 (en) | Method for sterilely producing lipid-nucleic acid particles | |
AU754563B2 (en) | Cationic lipid formulation delivering nucleic acid to peritoneal tumors | |
JP2017523965A (en) | Method of encapsulating nucleic acid in lipid nanoparticle host | |
US20200283795A1 (en) | Plant virus movement proteins and methods of using same | |
KR20100085079A (en) | Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same | |
Lepeltier et al. | Self-assembly of squalene-based nucleolipids: relating the chemical structure of the bioconjugates to the architecture of the nanoparticles | |
EP1867726A1 (en) | Liposome capable of effective delivery of given substance into nucleus | |
Koynova et al. | Recent patents in cationic lipid carriers for delivery of nucleic acids | |
Jääskeläinen et al. | Physicochemical and morphological properties of complexes made of cationic liposomes and oligonucleotides | |
Labas et al. | Nature as a source of inspiration for cationic lipid synthesis | |
WO1998045463A1 (en) | Composition for gene introduction into cell | |
Koynova et al. | Enhancing nucleic acid delivery, insights from the cationic phospholipid carriers | |
CA2595084A1 (en) | Method for coating particle with lipid film | |
TW202329986A (en) | Lipid compounds and lipid nanoparticle compositions | |
US20230255999A1 (en) | Dna compositions and related methods | |
Yanagihara et al. | Liposome-mediated gene transfer | |
Zabala-Ferrera et al. | Effects of Ion Concentration and Headgroup Chemistry on Thin Lipid Film Drainage | |
Andrilli et al. | Differential effects of the lipidic and ionic microenvironment on NPP1's phosphohydrolase and phosphodiesterase activities | |
JP2009221165A (en) | Packaging method of single-gene nanoparticle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20010909A Country of ref document: HR |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/01152/DE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2377422 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027000210 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 72718/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-292 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002102449 Country of ref document: RU Kind code of ref document: A |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2002-292 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020027000210 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |